Aptamer-based Bioadsorber
Not Specified
DiscoveryActive
Key Facts
About NanoGroup
NanoGroup is a publicly traded Polish biotech firm developing a diversified pipeline based on two core nanotechnology platforms: the NanOX system for organ preservation and transport of respiratory gases, and polysaccharide nanoparticle conjugates for targeted oncology. The company is in a pre-revenue, pre-clinical stage, actively raising capital and progressing multiple programs toward key 2026/2027 milestones. Its strategy involves building a group of subsidiaries (NanoSanguis, NanoVelos) to advance its platforms while also making strategic investments, such as in Auxilius Pharma's cardiovascular drug program.
View full company profileTherapeutic Areas
Other Not Specified Drugs
| Drug | Company | Phase |
|---|---|---|
| FL116 | Forlong Biotechnology | Not specified |
| FL117 | Forlong Biotechnology | Not specified |
| FL118 | Forlong Biotechnology | Not specified |
| FL301 | Forlong Biotechnology | Not specified |
| JSKN016 | AlphaMab Oncology | Phase 1 |
| JSKN033 | AlphaMab Oncology | Phase 1 |
| JSKN022 | AlphaMab Oncology | Phase 1 |
| JSKN027 | AlphaMab Oncology | Phase 1 |
| KN019 | AlphaMab Oncology | Phase 1 |
| New TCM Formulations | China SXT Pharmaceuticals | Research / Pre-clinical |
| Long-acting Leronlimab | CytoDyn | Preclinical |
| SR2162 | SIMR (Australia) Biotech | IND Approved |